Skip to main content

JAK Inhibition in Rheumatoid Arthritis

Current Rheumatology Reports volume 13, pages 379–380 (2011)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69:413–6.

    PubMed  Article  CAS  Google Scholar 

  2. Kremer JM, Cohen S, Wilkinson B, et al: Safety and efficacy after 24 weeks dosing of oral JAK inhibitor CP-690,550 in combination with methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2009, 60(S719):1925 (abstract).

    Google Scholar 

  3. Tanaka Y, Suzuki M, Nakamura H, et al: The oral JAK inhibitor CP-690,550 in combination with methotrexate is efficacious, safe and well tolerated in Japanese patients with active rheumatoid arthritis with an inadequate response to MTX alone. Abstract presented at the European League Against Rheumatism, Copenhagen, Denmark, June 10–13, 2009.

  4. Kanik K, Fleschmann RM, Cutolo M, et al: Phase 2B dose ranging monotherapy study of the oral JAK inhibitor CP-690,550 or adalimumab vs placebo in patients with active rheumatoid arthritis with an inadequate reponse to DMARDs. Ann Rheum Dis 2009, 68:123 OP-0159 (abstract).

    Google Scholar 

  5. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24:513–26.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Rheumatology and Clinical Immunology, University of Pittsburgh, S711 Biomedical Science Tower, 3500 Terrace Street, Pittsburgh, PA, 15261, USA

    Aarat M. Patel, Daniel Lupash, Douglas Chew, Marc C. Levesque & Larry W. Moreland

Authors
  1. Aarat M. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Lupash
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas Chew
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc C. Levesque
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Larry W. Moreland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larry W. Moreland.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Patel, A.M., Lupash, D., Chew, D. et al. JAK Inhibition in Rheumatoid Arthritis. Curr Rheumatol Rep 13, 379–380 (2011). https://doi.org/10.1007/s11926-011-0196-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0196-4

Keywords

  • Rheumatoid Arthritis Patient
  • Adalimumab
  • Active Rheumatoid Arthritis
  • Tumor Necrosis Factor Inhibitor
  • ACR20 Response